FORT LAUDERDALE, Fla., March 28 -- Imaging Diagnostic Systems Inc. announced it has signed a collaboration agreement with Schering AG, Germany, to evaluate the advantages of new fluorescence dyes developed by Schering for their potential to detect breast cancer. Imaging Diagnostics' CTLM system will be used in conjunction with Schering AG's dyes during clinical trials. The collaboration will assist in determining the potential benefits of using both technologies to enhance the CTLM system's capability to detect breast cancer.